Global Liver Fibrosis Corticosteroids Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Liver Fibrosis Corticosteroids Market Size

• The global liver fibrosis corticosteroids market was valued at USD 1.52 billion in 2024 and is expected to reach USD 3.89 billion by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 12.48%, primarily driven by the rising autoimmune hepatitis cases.
• This growth is driven by factors such as growing need due to increasing prevalence of chronic liver diseases and growing adoption of corticosteroids in clinical guidelines

Liver Fibrosis Corticosteroids Market Analysis

• Liver fibrosis corticosteroids refer to corticosteroid medications used to treat liver fibrosis; a condition characterized by excessive accumulation of extracellular matrix proteins that leads to scarring of the liver. These steroids, such as prednisone and budesonide, help reduce inflammation and immune response, particularly in cases such as autoimmune hepatitis, which is a significant contributor to liver fibrosis.
• The global liver fibrosis corticosteroids market is experiencing substantial growth, projected to expand at a CAGR of 12.48% over the coming years. This growth is primarily driven by the rising prevalence of autoimmune liver diseases and chronic conditions such as non-alcoholic steatohepatitis (NASH) and hepatitis B and C.
• Increasing awareness about early diagnosis and advancements in treatment protocols are further fueling market expansion. In addition, ongoing clinical trials exploring combination therapies involving liver fibrosis corticosteroids are opening new avenues for treatment.
• North America currently dominates the market, attributed to robust healthcare infrastructure and higher diagnosis rates. Meanwhile, Asia-Pacific is expected to witness the fastest growth due to increasing healthcare investments and a growing patient population. Overall, the market outlook remains optimistic, supported by strong research initiatives and evolving therapeutic strategies.

Report Scope and Liver Fibrosis Corticosteroids Market Segmentation       

Фиброз печени Тенденции рынка кортикостероидов

«Растущее использование комбинированной терапии»

• Одной из заметных тенденций на рынке кортикостероидов для лечения фиброза печени является растущее использование комбинированной терапии для повышения эффективности лечения. Кортикостероиды для лечения фиброза печени, в первую очередь используемые для контроля воспаления при таких заболеваниях печени, как аутоиммунный гепатит, теперь часто сочетаются с иммунодепрессантами, такими как азатиоприн. Такой подход помогает достичь лучшего контроля над заболеванием и снизить дозировку кортикостероидов, тем самым минимизируя долгосрочные побочные эффекты.
• Растущее принятие комбинированных терапий отражает сдвиг в сторону более персонализированных и целевых стратегий лечения. Клинические испытания продолжают изучать эти комбинации, стремясь более эффективно замедлить прогрессирование фиброза.
• Например, исследования показали, что сочетание преднизолона с азатиоприном значительно улучшает показатели ремиссии у пациентов с аутоиммунным заболеванием печени, которое является основной причиной фиброза .
• As healthcare providers increasingly recognize the benefits of these multi-drug regimens, the demand for combination therapies is expected to rise, driving further innovation and growth within the liver fibrosis corticosteroids market.

Liver Fibrosis Corticosteroids Market Dynamics

Driver

“Increasing Prevalence of Chronic Liver Diseases”

• The increasing prevalence of chronic liver diseases such as autoimmune hepatitis, non-alcoholic steatohepatitis (NASH), and hepatitis B and C is significantly contributing to the rising demand for liver fibrosis corticosteroids
• As unhealthy lifestyle habits, obesity, and metabolic disorders become more common globally, the incidence of liver fibrosis continues to escalate, prompting greater reliance on corticosteroid therapies to manage inflammation and slow disease progression
• Autoimmune hepatitis, in particular, is a major cause of liver fibrosis, and corticosteroids such as prednisone remain the first-line treatment to control immune-mediated liver damage
• The ongoing advancements in diagnostic tools and liver disease screening programs are leading to earlier detection of fibrosis, thereby increasing the timely use of corticosteroid-based therapies
• As more patients are diagnosed at treatable stages, the demand for liver fibrosis corticosteroids rises, supporting improved patient outcomes and reducing the risk of progression to cirrhosis

For instance,

• In June 2023, according to an article published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 2 in 100,000 people are diagnosed with autoimmune hepatitis annually, with corticosteroids being the primary treatment to manage inflammation and prevent fibrosis progression
• In September 2022, according to the World Health Organization (WHO), over 296 million people worldwide were living with chronic hepatitis B infection, a major risk factor for liver fibrosis, thereby driving the need for effective corticosteroid therapies to control immune-related liver damage 
• As a result of the increasing prevalence of chronic liver diseases such as autoimmune hepatitis, NASH, and hepatitis infections, there is a significant rise in the demand for liver fibrosis corticosteroids

Opportunity

“Development of Targeted Corticosteroid Formulations”

• The development of targeted corticosteroid formulations offers the potential to minimize side effects and enhance treatment efficacy for liver fibrosis patients
• Advanced drug delivery systems, such as nanoparticle-based or liver-specific formulations, can help concentrate corticosteroids directly in hepatic tissue, reducing systemic exposure and improving patient safety
• In addition, these innovations can enable controlled release of corticosteroids, maintaining therapeutic levels over extended periods and reducing the frequency of dosing

For instance,

• In February 2024, according to an article published in the Journal of Hepatology, researchers successfully developed a liver-targeted nanoparticle delivery system for corticosteroids, which significantly reduced systemic side effects while effectively suppressing hepatic inflammation and fibrosis progression. This breakthrough demonstrates the potential of advanced formulations to enhance patient compliance and therapeutic outcomes
• In October 2023, according to an article published by Frontiers in Pharmacology, scientists highlighted the promise of precision drug delivery methods in liver diseases, noting that targeted corticosteroid delivery could revolutionize fibrosis management by increasing drug concentration at the disease site while minimizing adverse effects 
• The advancement of targeted corticosteroid formulations presents a significant opportunity to improve treatment outcomes for liver fibrosis patients, enhance drug safety profiles, and expand market potential globally

Restraint/Challenge

“Potential Side Effects and Long-Term Risks Associated with Corticosteroid”

• The potential side effects and long-term risks associated with corticosteroid use pose a significant challenge for the liver fibrosis corticosteroids market, particularly impacting patient adherence and physician prescribing behavior
• Prolonged corticosteroid therapy can lead to serious complications such as osteoporosis, diabetes, hypertension, and increased susceptibility to infections
• These adverse effects often necessitate careful patient monitoring and may limit the duration and dosage of corticosteroid treatment, reducing their appeal as a long-term therapy option for liver fibrosis

For instance,

• In August 2023, according to an article published by the National Library of Medicine, long-term corticosteroid use was associated with a 1.9-fold increased risk of developing osteoporosis and fractures, which raises concerns about the chronic use of these drugs in managing liver fibrosis
• Consequently, such safety concerns can result in healthcare providers opting for alternative treatments or combination therapies, potentially limiting the growth and widespread adoption of corticosteroids in liver fibrosis management

Liver Fibrosis Corticosteroids Market Scope

The market is segmented on the basis of drug type, disease type, route of administration, and end user.

Liver Fibrosis Corticosteroids Market Regional Analysis

“North America is the Dominant Region in the Liver Fibrosis Corticosteroids Market”

• North America stands out as the dominant region in the liver fibrosis corticosteroids market, primarily due to its advanced healthcare infrastructure, high disease awareness, and robust research and development landscape
• U.S., in particular, leads the market with a substantial patient population suffering from chronic liver conditions such as non-alcoholic steatohepatitis (NASH), hepatitis B and C, and autoimmune hepatitis
• The availability of advanced diagnostic tools enables early detection and timely intervention, increasing the demand for corticosteroid therapies. Moreover, favorable reimbursement policies and proactive government initiatives aimed at liver disease management further strengthen the market position
• Major pharmaceutical companies and academic institutions in the region are heavily investing in the development of targeted corticosteroid formulations, ensuring continued innovation 
• For instance, ongoing clinical trials focusing on liver-specific corticosteroid delivery systems are gaining traction in the U.S., reinforcing North America's leadership in this rapidly evolving therapeutic area

“Asia-Pacific is Projected to Register the Highest Growth Rate”

• Asia-Pacific is projected to register the highest growth rate in the liver fibrosis corticosteroids market, driven by a rising prevalence of liver diseases, increasing healthcare expenditure, and improving access to advanced therapies.
• Rapid urbanization and changing lifestyles have led to a surge in risk factors such as obesity, diabetes, and alcohol consumption, contributing to higher incidences of liver fibrosis.
• Countries such as China, India, and Japan are investing heavily in healthcare infrastructure and research initiatives to combat liver diseases. In addition, growing awareness campaigns and early screening programs are enhancing diagnosis rates.
• China is projected to register the highest growth rate in the liver fibrosis corticosteroids market, driven by rising liver disease prevalence, healthcare investments, and increasing adoption of advanced treatment options.
• The expanding pharmaceutical sector and favorable government policies supporting drug development and approval processes further accelerate market growth across the region.

Liver Fibrosis Corticosteroids Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Boehringer Ingelheim International GmbH (Germany)
• Gilead Sciences, Inc. (U.S.)
• Gyre Therapeutics, Inc. (U.S.)
• Galectin Therapeutics Inc. (U.S.)
• Hepion Pharmaceuticals (США)
• Intercept Pharmaceuticals, Inc. (США)
• Ionis Pharmaceuticals (США)
• Inventiva (Франция)
• Лилли (США)
• Madrigal Pharmaceuticals (США)
• Merck & Co., Inc. (США)
• Novo Nordisk A/S (Дания)
• Новартис АГ (Швейцария)
• Pfizer Inc. (США)
• Pharmaxis Group USA (США)
• Ривус Фармасьютикалс (США)
• Torrent Pharmaceuticals Ltd. (Индия)
• В.Б.Шилпа (Индия)
• ZEALAND PHARMA (Дания)
• Группа Zydus (Индия)

Последние разработки на мировом рынке кортикостероидов для лечения фиброза печени

• В марте 2022 года исследование, опубликованное на PubMed, сообщило, что в рандомизированном открытом исследовании комбинация кортикостероидов с глицирризином была оценена на предмет ее эффективности в лечении хронического поражения печени, вызванного лекарственными средствами или травами. Результаты продемонстрировали значительные биохимические и гистологические улучшения, указывающие на то, что эта комбинированная терапия может быть полезна при лечении фиброза печени, возникающего в результате таких повреждений.

SKU-73819